biote (NASDAQ:BTMD) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

biote (NASDAQ:BTMD) posted its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.17, FiscalAI reports. The firm had revenue of $47.96 million for the quarter, compared to the consensus estimate of $47.76 million. biote had a negative return on equity of 21.00% and a net margin of 15.73%. biote updated its FY 2025 guidance to EPS.

biote Trading Down 3.7%

Shares of BTMD stock traded down $0.11 on Friday, reaching $2.74. The company had a trading volume of 57,584 shares, compared to its average volume of 159,859. The stock has a market cap of $135.22 million, a PE ratio of 3.04 and a beta of 1.15. The company has a 50-day moving average of $3.07 and a 200-day moving average of $3.52. biote has a 12 month low of $2.65 and a 12 month high of $6.98.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BTMD shares. Weiss Ratings raised biote from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, October 24th. Wall Street Zen cut biote from a “buy” rating to a “hold” rating in a report on Sunday, November 2nd. Finally, B. Riley restated a “neutral” rating on shares of biote in a research report on Thursday. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On biote

Large investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC boosted its position in shares of biote by 142.1% during the second quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock worth $487,000 after purchasing an additional 71,053 shares in the last quarter. Man Group plc grew its stake in biote by 419.1% in the second quarter. Man Group plc now owns 64,027 shares of the company’s stock valued at $257,000 after acquiring an additional 51,693 shares during the period. Geode Capital Management LLC increased its holdings in shares of biote by 7.2% in the second quarter. Geode Capital Management LLC now owns 616,697 shares of the company’s stock worth $2,480,000 after acquiring an additional 41,333 shares in the last quarter. Topline Capital Management LLC bought a new stake in shares of biote in the second quarter worth about $115,000. Finally, Marshall Wace LLP raised its position in shares of biote by 26.6% during the second quarter. Marshall Wace LLP now owns 118,928 shares of the company’s stock worth $478,000 after purchasing an additional 24,954 shares during the period. Institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.